Focusing on orphan and ultra-orphan drugs, this event will provide a fresh perspective on one of the industry`s hottest areas for market & patient access. Communicating value and cost-effectiveness with regulators, payers, HTA bodies and other key stakeholders, in such niche markets, requires innovation & a clearly defined process to ensure the message is achieved.
The event will be focused purely on orphan therapies and will guarantee all participants access to today`s most relevant case studies and views which directly affect their future business plans and can assist them to maximise market and patient access.
Why attend?
- Prioritise key markets based on payer willingness to reward innovation for niche therapies
- Evaluate current patient compliance programs and understand which models are working to generate the best data and therefore the strongest value argument
- Hear policy makers` views, initiatives and incentives for orphan drug development and approval
- Enhance your global/local pricing and reimbursement strategy for your niche product
- Enhance communication of your products` value by quantifying overall cost of treatment and therefore cost-effectiveness to payers and HTAs to justify pricing levels
- Develop a clear plan to improves stakeholder relations and effectively utilise patient groups
- Network and build stronger relationships within this targeted segment of the pharma industry
Visitors profileVice-Presidents, Directors, Managers involved in Orphan treatments: Pricing & Reimbursement, Health Economics & Outcomes, Government & Stakeholder Relations, Regulatory Affairs, Medical Affairs, Public Policy, Marketing, Therapy Area Heads, Market Access
